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Wouter A. Dreschler, PhD,2 and Ben A. Schmand, PhD1,3
Objective: This follow-up study of the European Dexamethasone Study was designed to examine the potential harmful effect of
adjunctive dexamethasone treatment on long-term neuropsychological outcome in adults with bacterial meningitis.
Methods: Neurological, audiological, and neuropsychological examinations were performed in adults who survived pneumococ-
cal or meningococcal meningitis.
Results: Eighty-seven of 99 (88%) eligible patients were included in the follow-up study; 46 (53%) were treated with dexa-
methasone and 41 (47%) with placebo. Median time between meningitis and testing was 99 months. Neuropsychological
evaluation showed no significant differences between patients treated with dexamethasone and placebo. The proportions of
patients with persisting neurological sequelae or hearing loss were similar in the dexamethasone and placebo groups. The overall
rate of cognitive dysfunction did not differ significantly between patients and control subjects; however, patients after pneumo-
coccal meningitis had a higher rate of cognitive dysfunction (21 vs 6%; p  0.05) and experienced more impairment of everyday
functioning due to physical problems (p  0.05) than those after meningococcal meningitis.
Interpretation: Treatment with adjunctive dexamethasone is not associated with an increased risk for long-term cognitive
impairment. Adults who survive pneumococcal meningitis are at significant risk for long-term neuropsychological abnormalities.
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The estimated incidence of bacterial meningitis is 2 to
5 per 100,000 adults per year.1–3 The predominant
causative pathogens in adults are Streptococcus pneu-
moniae and Neisseria meningidis, which cause 80 to
85% of all cases.1,4 Reported mortality rates are high
(20–30%), and neurological sequelae occur in a high
proportion of surviving patients (15–40%).1,4 Cogni-
tive impairment occurs frequently after bacterial men-
ingitis.2 In one prospective study, cognitive impair-
ment was detected in 27% of adults who had a good
recovery from pneumococcal meningitis.5 In this study,
cognitive impairment consisted mainly of cognitive
slowness, which was related to lower scores on ques-
tionnaires measuring the quality of life. Patients after
meningococcal meningitis were not significantly differ-
ent from control subjects.5
A European randomized, placebo-controlled trial in-
volving 301 adults with suspected meningitis showed
that adjunctive treatment with dexamethasone before
or with the first dose of antimicrobial therapy reduced
the risk for an unfavorable outcome from 25 to 15%.6
Mortality was reduced from 15 to 7%. In a recent
quantitative review of this topic, treatment with corti-
costeroids was associated with a significant reduction in
mortality and neurological sequelae.7 Since publica-
tions of these results, adjunctive dexamethasone has be-
come routine therapy in adults with suspected bacterial
meningitis.2,6,8
Corticosteroids may potentiate ischemic and apopto-
tic injury to neurons.9 In a model of pneumococcal
meningitis in infant rats, adjunctive dexamethasone ag-
gravated neuronal apoptosis in the hippocampal den-
tate compared with antibiotic therapy alone.10 In-
creased hippocampal cell injury caused by
dexamethasone was related to a reduced learning capac-
ity in this model.10 The effect of adjunctive dexameth-
asone therapy on cognitive outcome in humans after
bacterial meningitis is unknown.2,7,11–14
This study was designed to examine the potential
harmful effects of adjunctive dexamethasone treatment
on long-term cognitive outcome in patients with bacte-
rial meningitis. Therefore, neurological, audiological,
and neuropsychological examinations were performed in
adults included in the European Dexamethasone Study
after pneumococcal or meningococcal meningitis.
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Subjects and Methods
Initial Study
The European Dexamethasone Study was a double-blind,
placebo-controlled trial of adjunctive dexamethasone therapy
for adults with bacterial meningitis. Eligible patients were
older than 17 years and had suspected meningitis in combi-
nation with cloudy cerebrospinal fluid (CSF), bacteria in
CSF on Gram staining, or a CSF leukocyte count greater
than 1,000/mm3.6 Patients were enrolled between June 1993
and December 2001. A total of 301 patients were randomly
assigned to receive dexamethasone sodium phosphate, at a
dose of 10mg given every 6 hours intravenously for 4 days,
or placebo. The study medication was given 15 to 20 min-
utes before or with the first dose of antibiotics. The primary
outcome measure was the score on the Glasgow Outcome
Scale (GOS) 8 weeks after randomization, as assessed by the
patient’s physician. This is a well-validated measurement
scale with a score range from 1 to 5: a score of 1 indicates
death; 2 is persistent vegetative state; 3 is severe disability; 4
is moderate disability (disabled but independent); and 5 is
good recovery (mild or no disability).15 A favorable outcome
was defined as a score of 5, and an unfavorable outcome as a
score of 1 to 4. CSF culture yielded S. pneumoniae in 108
patients (36%), N. meningitidis in 97 patients (32%), and
other bacteria in 31 patients (10%); CSF cultures remained
negative in 65 patients (22%). Treatment with dexametha-
sone was associated with a reduction in the risk for an un-
favorable outcome (relative risk, 0.6; 95% confidence inter-
val, 0.3–0.9; p  0.03) and mortality (relative risk, 0.48;
95% confidence interval, 0.2–0.96; p  0.04).6
Follow-up Study
Patients eligible for this follow-up study were older than 17
years living in the Netherlands who survived pneumococcal
or meningococcal meningitis, confirmed by CSF culture. Ex-
clusion criteria were serious illnesses other than meningitis
interfering with cognitive testing, pre-existing psychiatric dis-
orders, evidence for alcoholism or other substance abuse, use
of sedatives or neuroleptic medication, and insufficient mas-
tery of the Dutch language. Patients were recruited by con-
tacting treating physicians, general practitioners, or through
municipality databases. The study was approved by the ethics
committee of the Academic Medical Center. For each of the
participating patients, 1 control subject was recruited from
partners, siblings, and close friends until a control group of
50 subjects was completed. All participants gave written, in-
formed consent. Patients and control subjects underwent a
tone and speech audiogram and a neuropsychological evalu-
ation by a psychologist (M.H.) who was blinded with respect
to the former treatment group (dexamethasone or placebo).
Whenever audiometry was performed, hearing loss was ex-
pressed as the average degree of pure-tone hearing loss of
high frequencies (1, 2, and 4kHz) on the most severely af-
fected side. Hearing loss was classified as follows: normal
(30dB), mild (30–55dB), moderate (55–70dB), severe
(70–90dB), or profound (90dB).16 Two experienced
physicians (M.W. and D.v.d.B.) performed a neurological
examination in patients. Focal neurological deficits were di-
vided into focal cerebral deficits (aphasia, monoparesis, or
hemiparesis) and cranial nerve palsies. Participants unable or
unwilling to travel to our hospital underwent a neuropsycho-
logical evaluation by our psychologist in a hospital near the
patients’ residences.
Neuropsychological Evaluation
Six cognitive domains were tested by the following test bat-
tery:
1. Intelligence: Current intelligence was tested by the
Groningen Intelligence Tests (GIT)–abbreviated ver-
sion, consisting of subtests for verbal and visuospatial
reasoning and numerical ability17; premorbid intelli-
gence was tested by the Dutch Adult Reading Test.18
2. Memory: The Rey’s Auditory Verbal Learning Test
(AVLT) and the subtest Story Recall from the River-
mead Behavioural Memory Test (RBMT) were used
to test verbal memory,19,20 visual memory was tested
by the subtest Visual Reproduction from the Wechsler
Memory Scale-Revised (WMS-R),19 and digit span
was assessed by the Wechsler Adult Intelligence Scale-
Revised (WAIS-R) Digit Span Test.21
3. Language: A short form of the Boston Naming Test
(BNT) was used to examine language function; the
score was extrapolated to the full-length score.22
4. Attention: Attention was assessed by the Trail Making
Test part B, Stroop Color Word Test part C (inter-
ference condition), and the Wechsler Adult Intelli-
gence Scale-Revised Digit Span Test.19,21
5. Executive functioning: Category and Letter fluency and
the Wisconsin Card Sorting Test (WCST) were used
to evaluate executive functioning.17,19
6. Psychomotor function: Trail Making Test part A,
Stroop Color Word Test parts A (word reading) and B
(color naming), Simple and 2-choice reaction tasks
evaluated psychomotor function.19 General health and
quality of life were evaluated by means of the
RAND-36 questionnaire23,24; the Profile of Mood
States (POMS) determined depressive mood disor-
ders.19 To explore whether measurement of cognitive
speed was biased by physical impairments, we tested
fine motor skills using the Grooved Pegboard.25
These tests are described in the Appendix.
Test results were expressed as standard T-scores corrected
for age and education with use of the control group to form
normative scores for the neuropsychological measures (mean
score in control subjects, 50; standard deviation, 10; a higher
score indicates better performance).26
Data Analysis
To examine relative differences between groups, we per-
formed multivariate analyses of variance (MANOVAs)
within each neuropsychological domain separately using
T-scores corrected for age and education. If multivariate
comparisons demonstrated significant results (p  0.05, Pil-
lais’ Trace two-tailed), t tests with Bonferroni correction for
the number of comparisons were performed to evaluate sin-
gle neuropsychological measures.
As a next step, we tested for statistical interaction between
treatment group (dexamethasone vs placebo) and the caus-
ative pathogen (S. pneumoniae vs N. meningitidis) by adding
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multiplicative interaction terms to the multivariate compari-
sons. Statistically significant interactions within a cognitive
domain were analyzed by linear regression with the individ-
ual neuropsychological measure as the dependent variable
and the interaction term as the independent variable. The
strength of the associations between treatment and test re-
sults within each patient group was expressed as regression
coefficients (a positive regression coefficient indicates a
higher score in the subgroup treated with adjunctive dexa-
methasone than in those receiving placebo).
A test score was categorized as impaired if at least two
standard deviations below the mean score of the control
group, after correction for age and education. Cognitive dys-
function was considered to be present if performance, re-
flected by the number of impaired test results, was worse
than the fifth centile of the control group. To compare cog-
nitive speed between groups, we formed a speed composite
score for each participant by calculation of a mean T-score of
tests in which cognitive speed is important, as described pre-
viously.5,27 Cognitive slowness was defined as a speed com-
posite score worse than the fifth centile of the control group,
after correction for age and education.
We hypothesized the existence of clinically significant cog-
nitive impairment for patients who recovered from bacterial
meningitis, with higher rates of cognitive impairment in pa-
tients receiving adjunctive dexamethasone than in those
treated with placebo.2,10 In addition, we hypothesized higher
rates of cognitive impairment in survivors of pneumococcal
meningitis compared with those after meningococcal menin-
gitis.5 For nonparametric testing, Mann–Whitney U, 2, or
Fisher’s exact statistics were used. Data collected at the time
of the original and follow-up studies were compared by the
Wilcoxon signed rank test. A sample of size of 25 patients in
each group is necessary to detect clinically relevant differ-
ences (effect size of 0.8 [defined as mean difference/standard
deviation]); univariate power of 0.80, and   0.05. For all
comparisons, two-tailed p values were used, and we consid-
ered p  0.05 to be statistically significant.
Role of the Funding Source
The funding source had no role in the study design; in the
collection, analysis, and interpretation of data; in the writing
of the report; or in the decision to submit this article for
publication.
Results
In the European study, 32 of 301 patients (11%) died
within 8 weeks after admission. Of 269 surviving pa-
tients, 177 (66%) had bacterial meningitis due to S.
pneumoniae (n  83) or N. meningitidis (n  94), as
proved by CSF culture (Fig); 26 patients (15%) could
not be reached. In addition, exclusion criteria were met
in 52 patients: death (n  19), residence outside the
Netherlands (n  11), somatic or psychiatric illnesses
Fig. Patient selection in study of long-term outcome after bacterial meningitis. aSystemic neoplasm (n  4), psychiatric disorders
(n  4), severe bilateral deafness (n  4), congenital deaf mutism (n  1), mental retardation (n  1), brain tumor (n  1),
rheumatoid arthritis (n  1), bullet in the head (n  1). bOne patient had insufficient mastery of Dutch language, and one pa-
tient was younger than 16 years. CSF  cerebrospinal fluid.
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not related to meningitis that impair cognitive testing
(n  17), history of alcoholism (n  2) or other sub-
stance abuse (n  1), insufficient mastery of the Dutch
language (n  1), or age younger than 16 years (n 
1; protocol violation of European study). In total, 99
patients were eligible for follow-up; of those eligible,
12 patients (12%) refused to participate (all had a
GOS score of 5, as assessed by telephonic interview).
Thus, 87 of 99 patients (88%) were included in this
follow-up study. Demographic characteristics (age and
sex), causative pathogens, and score on the GOS (8
weeks after discharge) were similar for eligible and par-
ticipating patients. A total of 50 control subjects were
recruited. Sex distribution (17 of 50 [34%] control
subjects were male; 43 of 87 [49%] patients were
male), age distribution (mean age, 49  15 years for
control subjects vs 47  16 years for patients), and
level of education (13.2  1.6 years for control sub-
jects vs 12.9  2.3 years for patients) were similar in
patients and control subjects.
Clinical characteristics at time of admission were
similar in the dexamethasone- and placebo-treated
groups (Table 1). Focal neurological deficits were
present in 23 of 87 patients (26%), and 10 patients
(12%) were comatose on admission. CSF results dem-
onstrated S. pneumoniae in 38 patients (44%) and N.
meningitidis in 49 (56%); 46 patients (53%) received
adjunctive dexamethasone and 41 (47%) received pla-
cebo. Eight weeks after discharge, focal neurological
deficits were present in 12 of 87 patients (14%). Out-
come was graded as favorable in 80 of 87 patients
(92%); 6 (7%) patients had a GOS score of 4, and 1
patient (1%) had a score of 3.
Neurological examination was performed in all pa-
tients in this follow-up study. The median time be-
tween discharge and neurological examination was 99
months (range, 30–146 months) and was similar in
both treatment groups. Neurological deficits were
present in 17 of 87 patients (20%); there were no dif-
ferences between treatment groups (Table 2). Eighty
patients (92%) had a GOS score of 5, and 7 (8%) had
a GOS score of 4. All patients with a GOS score of 4
had neurological sequelae; two patients had focal cere-
bral deficits, and the additional five patients had cra-
nial nerve palsies. Ten patients (11%) had only slight
hearing impairment without significant interference in
daily life: These patients also received a GOS score of
5. Most patients had similar scores on the GOS com-
pared with the evaluation 8 weeks after admission
(p  0.76). Patients after pneumococcal meningitis
had a higher rate of focal neurological deficits and were
more likely to have a GOS score of 4 than those after
meningococcal meningitis.
Audiological examination was performed in all par-
ticipants who were able/willing to travel to our hospi-
tal: 51 of 87 patients (59%) and 35 of 50 control sub-
jects (70%; Table 3). The degree of hearing loss in
survivors of bacterial meningitis was similar to that in






Characteristics on admission in initial study
Mean age at time of meningitis (SD), yr 42 16 38  18
Alcoholism or substance abuse, n 0 0
Sex: M/F 19/27 24/17
Mean Glasgow Coma Scale score (SD) 11 3 11 3
Coma, n (%) 6 (13) 4 (10)
Focal neurological abnormalities, n (%) 12 (26) 11 (27)
Focal cerebral deficits,a n (%) 10 (22) 8 (20)
Cranial nerve palsies, n (%) 4 (9) 5 (12)
Laboratory results
Streptococcus pneumoniae in CSF culture, n (%) 22 (48) 16 (39)
Neisseria meningitidis in CSF culture, n (%) 24 (52) 25 (61)
Mean CSF leukocyte count (SD), 103 cells/mm3 23  26 24 26
Mean CSF protein level (SD), gm/L 4.6 3.3 5.2 3.3
Mean CSF glucose level (SD), mg/dl 1.3 1.7 1.1  1.2
Positive blood culture, n (%) 26/38 (68) 22/38 (58)
Neurological findings at discharge in initial study
GOS score 3, n (%) 1 (2) 0
GOS score 4, n (%) 2 (4) 4 (10)
GOS score 5, n (%) 43 (94) 37 (90)
Focal neurological abnormalities, n (%) 6 (13) 6 (15)
Focal cerebral deficits,a n (%) 1 (2) 1 (2)
Cranial nerve palsies, n (%) 5 (11) 6 (15)
aDefined as aphasia, monoparesis, or hemiparesis. SD  standard deviation; CSF  cerebrospinal fluid; GOS  Glasgow Outcome Scale.
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control subjects (median, 13 [range, 0–87] vs 10
[range, 2–35dB]; p  0.41). The median degree of
hearing loss was higher in adults surviving pneumococ-
cal meningitis than in those after meningococcal men-
ingitis (median, 18 [range, 2–87] vs 8 [range,
0–62dB]; p  0.01). The degree of hearing loss was
similar in patients treated with dexamethasone and pla-
cebo (median, 13 [range, 0–72] vs 13 [range,
0–87dB]; p  0.76).
Neuropsychological examination was performed in
all patients and control subjects. Demographic charac-
teristics and interval between meningitis and testing for
patients treated with dexamethasone and placebo were
similar (Table 4). MANOVAs within neuropsycholog-
ical domains showed no significant overall group dif-
ferences between both treatment groups for “intelli-
gence” (p  0.06), “memory” (p  0.15), “executive
functioning” (p  0.08), “attention” (p  0.68), and
“psychomotor speed” (p  0.72). Both treatment
groups also had similar scores on questionnaires for
general health and quality of life (RAND-36). Patients
who received adjunctive dexamethasone had higher
scores on the item “depression” than those with pla-
cebo (p  0.04); results of the multivariate analyses for
the cognitive domains remained similar after correction
for depression scores.
The number of impaired test results for both treat-
ment groups was similar as well (Table 5). Based on
performance in the control group, a patient was con-
sidered to have cognitive dysfunction if he or she had
three or more impaired test results. According to these
criteria, cognitive dysfunction was present in 4 of the
46 (9%) patients treated with dexamethasone com-
pared with 7 of 41 patients in the placebo group (17%;
p  0.24). Both treatment groups had similar results
on the speed composite score (p  0.14). Performance
on the speed composite score showed no significant
correlations with performance on the Grooved Peg-
board and scores on the item “depression” of the
POMS.
In patients with pneumococcal meningitis, demo-
graphic characteristics were similar in both treatment
groups, although the interval between meningitis and
testing was longer in those treated with dexamethasone
(p  0.04; Table 6). MANOVAs within neuropsycho-
logical domains showed significant overall group differ-
ences between both treatment groups for “memory”
(p  0.004) and “executive functioning” (p  0.01),















Focal neurological deficits, n (%) 10 (22) 7 (17) 13 (34) 4 (8)a
Focal cerebral deficits,b n (%) 1 (2) 1 (2) 2 (5) 0
Cranial nerve palsies, n (%) 10 (22) 7 (17) 13 (34) 4 (8)a
GOS score, 5:4 43:3 37:4 32:6 48:1c
Comparison of pneumococcal versus meningococcal meningitis patients:
ap  0.002, 2 test two-tailed;
cp  0.04, Fisher’s exact test two-tailed.
bSlight hemiparesis in combination with hearing loss in both cases.
GOS  Glasgow Outcome Scale.




















Degree of pure-tone hearing loss, n (%)
30dB 32 (91) 18 (75) 20 (74) 16 (64) 22 (85)
30-55dB 3 (9) 4 (17) 5 (19) 6 (24) 3 (12)
55-70dB 0 1 (4) 1 (4) 1 (4) 1 (4)
70-90dB 0 1 (4) 1 (4) 2 (8) 0
Median speech recognition threshold
(range), dB
65 (50–90) 70 (50–120) 65 (50–120) 70 (50–120) 65 (50–110)
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but not for “intelligence” (p  0.52), “attention” (p 
0.68), and “psychomotor speed” (p  0.86). Results of
the multivariate analyses for the cognitive domains re-
mained similar after correction for the interval between
meningitis and testing. Pneumococcal meningitis pa-
tients who were treated with dexamethasone performed
significantly better on the AVLT recognition than
those treated with placebo (p  0.004, Bonferroni cor-
rection). Performance on the other neuropsychological
tests within the domains of “memory” and “executive
functioning” was similar in both treatment groups.
In patients with meningococcal meningitis, demo-
Table 5. Number of Impaired Tests in Control Subjects and













0 32 (64%) 21 (46%) 21 (51%)
1 11 (22%) 12 (26%) 9 (22%)
2 5 (10%) 9 (20%) 4 (10%)
3 1 (2%) 3 (7%) 2 (5%)
4 1 (2%) 1 (2%) 5 (12%)






(N  41) pa
Demographic characteristics
Mean age at time of testing (SD), yr 49.7 (15.9) 44.7 (16.7) 0.16
Mean education (SD), yr 13.0 (2.1) 12.9 (2.6) 0.81
Median months from meningitis to testing (range) 100.0 (39–146) 98.0 (30–140) 0.37b
Mean premorbid intelligence (IQ) (SD) 102.1 (18.2) 96.5 (14.5) 0.12
Mean intelligence score (SD): GIT
Intelligence (IQ) 108.2 (15.8) 107.8 (14.8) 0.93
Verbal reasoning 50.6 (8.7) 51.8 (12.2) 0.60
Visuospatial reasoning 48.1 (10.3) 52.8 (14.0) 0.09
Numerical speed 47.0 (11.0) 50.5 (10.0) 0.14
Mean memory score (SD)
Rey’s AVLT immediate 45.4 (9.5) 46.5 (8.7) 0.59
Rey’s AVLT delayed 47.2 (8.2) 46.4 (9.6) 0.65
Rey’s AVLT recognition 48.0 (10.8) 43.6 (14.0) 0.10
WMS-R immediate 50.9 (7.9) 51.3 (6.3) 0.82
WMS-R delayed 50.3 (8.6) 50.3 (9.9) 0.99
RBMT immediate 50.4 (8.8) 50.9 (11.3) 0.80
RBMT delayed 50.5 (10.1) 49.1 (11.7) 0.56
WAIS-R Digit Symbol Test 47.6 (9.8) 50.4 (9.2) 0.20
Mean language score (SD): Boston Naming Test 50.8 (14.2) 47.6 (17.0) 0.35
Mean attention score (SD)
Trail Making Test part B 44.3 (12.9) 46.7 (12.7) 0.39
SCWT part C (interference condition) 47.8 (13.1) 48.1 (15.4) 0.94
WAIS-R Digit Span Test 47.6 (9.8) 50.4 (9.2) 0.35
Mean executive functioning score (SD)
Category fluency 52.7 (11.9) 51.3 (10.9) 0.57
Letter fluency 48.5 (9.3) 48.5 (9.1) 0.97
Number of WCST categories 50.6 (9.8) 48.9 (9.3) 0.45
Number of WCST total errors 53.1 (9.2) 47.4 (11.6) 0.02
Number of WCST perseverative errors 49.5 (8.9) 45.1 (12.1) 0.07
Mean psychomotor speed score (SD)
Trail Making part A 47.6 (11.0) 46.6 (11.9) 0.69
SCWT Test part A (word reading) 47.6 (11.3) 48.4 (10.3) 0.74
SCWT part B (color naming) 46.6 (12.7) 46.7 (10.1) 0.39
Visual reaction task, dominant hand 47.1 (10.2) 48.5 (10.2) 0.54
Visual reaction task, nondominant hand 47.2 (11.9) 50.0 (8.5) 0.23
Binary choice reaction task 50.5 (12.1) 48.5 (12.4) 0.47
Scores are expressed as T-scores corrected for age and education.
aTwo-tailed p values (t test)
bTwo-tailed p value of Mann–Whitney U test.
SD  standard deviation; IQ  intelligence quotient; GIT  Groningen Intelligence Tests; AVLT  Auditory Verbal Learning Test; WMS-
R  Wechsler Memory Scale-Revised; RBMT  Rivermead Behavioural Memory Test; WAIS-R  Wechsler Adult Intelligence Scale-Revised;
SCWT  Stroop Color Word Test; WCST  Wisconsin Card Sorting Test.
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graphic characteristics in patients treated with dexa-
methasone and placebo were similar (Table 7).
MANOVAs within neuropsychological domains
showed no significant overall group differences be-
tween both treatment groups for “intelligence” (p 
0.23), “memory” (p  0.23), “executive functioning”
(p  0.50), “attention” (p  0.99), and “psychomotor
speed” (p  0.32).
The interaction between the causative pathogen and
treatment group was significant for the multivariate
comparison of test results within the domain of “mem-
ory” (p  0.007), but not within any of the other
cognitive domains (p  0.55 for all). In a linear re-
gression analysis, this interaction was significant for
performance on two subtests of the AVLT. Dexameth-
asone therapy was associated with higher scores on the
AVLT immediate recall in patients after pneumococcal
meningitis and with lower scores on the same test in
survivors of meningococcal meningitis; regression coef-
ficient in the subgroup of pneumococcal patients was
0.23 compared with 0.25 within meningococcal pa-
tients (p interaction  0.03). Similar associations were
found for performance on the AVLT recognition (re-
gression coefficient of 0.46 in pneumococcal patients






(N  16) pa
Demographic characteristics
Mean age at time of testing (SD), yr 56.5 (13.5) 53.9 (15.7) 0.59
Mean education (SD), yr 12.3 (2.3) 12.0 (3.2) 0.72
Median months from meningitis to testing (range) 104 (40–141) 71.0 (36–140) 0.04b
Mean premorbid intelligence (IQ) score 101.0 (17.4) 99.2 (17.9) 0.75
Mean intelligence score (SD): GIT
Intelligence (IQ) 106.7 (15.5) 105.6 (15.8) 0.84
Verbal reasoning 48.8 (8.6) 51.8 (12.3) 0.39
Visuospatial reasoning 48.7 (11.9) 54.5 (13.9) 0.20
Numerical speed 44.5 (10.7) 46.4 (9.8) 0.59
Mean memory score (SD)
Rey’s AVLT immediate 45.2 (8.9) 41.1 (8.6) 0.16
Rey’s AVLT delayed 46.7 (7.1) 42.0 (9.0) 0.08
Rey’s AVLT recognition 49.4 (11.6) 36.6 (13.6) 0.0004
WMS-R immediate 49.4 (9.0) 50.5 (6.8) 0.71
WMS-R delayed 47.8 (10.0) 48.8 (14.0) 0.82
RBMT immediate 50.5 (6.6) 51.2 (11.3) 0.82
RBMT delayed 51.0 (7.3) 52.0 (13.7) 0.79
WAIS-R Digit Span Test 48.1 (9.7) 53.3 (11.4) 0.16
Mean language score (SD): Boston Naming Test 51.6 (12.7) 43.9 (19.9) 0.16
Mean attention score (SD)
Trail Making Test part B 40.6 (12.6) 43.9 (17.8) 0.50
SCWT part C (interference condition) 47.3 (13.1) 46.4 (20.4) 0.87
WAIS-R Digit Span Test 48.1 (9.7) 53.3 (11.4) 0.16
Mean executive functioning score (SD)
Category fluency 55.8 (10.3) 50.3 (10.4) 0.11
Letter fluency 48.6 (10.9) 46.5 (10.9) 0.59
Number of WCST categories 52.8 (12.1) 51.1 (11.5) 0.67
Number of WCST total errors 54.1 (11.4) 46.7 (14.0) 0.09
Number of WCST perseverative errors 49.1 (11.7) 44.2 (14.7) 0.28
Mean psychomotor speed score (SD)
Trail Making part A 44.3 (12.5) 43.1 (14.8) 0.79
SCWT Test part A (word reading) 47.9 (13.7) 48.4 (9.8) 0.91
SCWT part B (color naming) 46.4 (14.3) 47.9 (6.9) 0.72
Visual reaction task, dominant hand 44.5 (12.9) 47.8 (12.7) 0.46
Visual reaction task, nondominant hand 45.9 (15.1) 49.0 (11.9) 0.52
Binary choice reaction task 49.9 (13.1) 45.6 (17.8) 0.40
Scores are expressed as T-scores corrected for age and education.
aTwo-tailed p values (t test).
bTwo-tailed p value of Mann–Whitney U test.
SD  standard deviation; IQ  intelligence quotient; GIT  Groningen Intelligence Tests; AVLT  Auditory Verbal Learning Test; WMS-
R  Wechsler Memory Scale-Revised; RBMT  Rivermead Behavioural Memory Test; WAIS-R  Wechsler Adult Intelligence Scale-Revised;
SCWT  Stroop Color Word Test; WCST  Wisconsin Card Sorting Test.
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vs 0.05 in meningococcal patients; p interaction 
0.01).
Control subjects and patients had similar scores on
premorbid intelligence (99.6  18 in control subjects
vs 99.5  17 in patients; p  0.96). MANOVAs
showed no significant differences between patients and
control subjects for “intelligence” (p  0.37), “mem-
ory” (p  0.31), “executive functioning” (p  0.06),
“attention” (p  0.15), and “psychomotor speed”
(p  0.38). Both groups had similar scores on the
RAND-36, the POMS, and the Grooved Pegboard.
Patients after pneumococcal meningitis were older
(p  0.0001) and had a lower level of education (p 
0.01) than those after meningococcal meningitis (Table
8). Sex distribution in both groups was similar.
MANOVAs showed significant overall group differ-
ences between survivors of pneumococcal meningitis
and meningococcal meningitis for “memory” (p 
0.01), but not for “intelligence” (p  0.12), “executive
functioning” (p  0.08), “attention” (p  0.12), and
“psychomotor speed” (p  0.22). Patients after pneu-
mococcal meningitis performed worse than those after
meningococcal meningitis on all tasks of the AVLT
and the Wechsler Memory Scale-Revised. These differ-






(N  25 ) pa
Demographic characteristics
Mean age at time of testing (SD), yr 43.5 (15.6) 38.8 (14.8) 0.29
Mean education (SD), yr 13.6 (1.8) 13.4 (1.9) 0.73
Median months from meningitis to testing (range) 100.0 (39–146) 114.0 (10–140) 0.52b
Mean premorbid intelligence (IQ) score (SD) 103.1 (19.3) 94.8 (12.1) 0.08
Mean intelligence score (SD): GIT
Intelligence (IQ) 109.5 (16.2) 109.1 (14.4) 0.94
Verbal reasoning 52.3 (8.6) 51.8 (‘r12.3) 0.87
Visuospatial reasoning 47.5 (8.8) 51.8 (14.2) 0.23
Numerical speed 49.4 (11.0) 53.3 (9.3) 0.21
Mean memory score (SD)
Rey’s AVLT immediate 45.6 (10.2) 50.0 (7.0) 0.09
Rey’s AVLT delayed 47.7 (9.3) 49.2 (9.0) 0.58
Rey’s AVLT recognition 46.8 (10.1) 47.8 (12.7) 0.75
WMS-R immediate 52.6 (6.4) 51.7 (6.1) 0.66
WMS-R delayed 52.9 (6.1) 51.0 (7.3) 0.36
RBMT immediate 50.2 (10.5) 50.7 (11.4) 0.45
RBMT delayed 50.0 (12.3) 47.5 (10.4) 0.87
WAIS-R Digit Span Test 47.2 (10.1) 48.7 (7.3) 0.57
Mean language score (SD): Boston Naming Test 50.1 (15.6) 50.1 (14.5) 0.99
Mean attention score (SD)
Trail Making Test part B 47.8 (12.5) 48.5 (7.9) 0.83
SCWT part C (interference condition) 48.3 (13.3) 49.1 (11.8) 0.84
WAIS-R Digit Span Test 47.2 (10.1) 48.7 (7.3) 0.57
Mean executive functioning score (SD)
Category fluency 49.8 (12.8) 51.8 (11.4) 0.55
Letter fluency 48.5 (7.9) 49.7 (7.7) 0.61
Number of WCST categories 48.4 (6.4) 47.6 (7.5) 0.71
Number of WCST total errors 52.0 (6.5) 47.8 (10.2) 0.12
Number of WCST perseverative errors 49.8 (5.0) 45.7 (10.5) 0.11
Mean psychomotor speed score (SD)
Trail Making part A 50.7 (8.4) 48.9 (9.4) 0.47
SCWT Test part A (word reading) 47.3 (8.4) 48.4 (10.9) 0.70
SCWT part B (color naming) 46.7 (11.1) 46.0 (11.7) 0.85
Visual reaction task, dominant hand 49.4 (6.3) 48.9 (8.5) 0.83
Visual reaction task, nondominant hand 48.3 (8.2) 50.7 (5.5) 0.26
Binary choice reaction task 51.0 (11.3) 50.5 (6.9) 0.85
Scores are expressed as T-scores corrected for age and education.
aTwo-tailed p values (t test).
bTwo-tailed p value of Mann–Whitney U test.
SD  standard deviation; IQ  intelligence quotient; GIT  Groningen Intelligence Tests; AVLT  Auditory Verbal Learning Test; WMS-
R  Wechsler Memory Scale-Revised; RBMT  Rivermead Behavioural Memory Test; WAIS-R  Wechsler Adult Intelligence Scale-Revised;
SCWT  Stroop Color Word Test; WCST  Wisconsin Card Sorting Test.
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ences remained similar after correction for score on the
speed composite measure, but they were no longer sig-
nificant after Bonferroni correction for the number of
comparisons. Patients who had pneumococcal menin-
gitis experienced more impairment of everyday func-
tioning due to physical problems (RAND-36; p 
0.05). Both groups had similar scores on the Grooved
Pegboard and the item “depression” of the POMS.
The proportion of cognitive dysfunction was higher in
patients after pneumococcal meningitis (8 of 38 [21%]
vs 3 of 49 [6%]; p  0.05). Survivors of pneumococcal
and meningococcal meningitis had similar results on
the speed composite score (p  0.09). Performance on
the speed composite score was significantly associated
with current intelligence in a linear regression analysis
(intelligence quotient; p  0.0001, two-tailed), but not
with the causative pathogen (p  0.10), time since
meningitis (p  0.67), dexamethasone therapy (p 
0.44), and GOS score (p  0.86).
Quality-of-life questionnaires demonstrated that pa-
tients who were defined as cognitively impaired had
higher scores on the item “depression” of the POMS
(p  0.003) and had lower scores on the RAND-36
on the subscales of social functioning (p  0.04),
mental health (p  0.004), and general health (p 
0.05).





(N  38) pa
Demographic characteristics
Mean age at time of testing (SD), yr 41.1 (15.2) 55.4 (14.3) 0.0001
Mean education (SD), yr 13.5 (1.8) 12.2 (2.7) 0.01
Median months from meningitis to testing (range) 110 (30–146) 88.5 (36–141) 0.20b
Mean premorbid intelligence (IQ) score (SD) 98.8 (16.3) 100.3 (17.4) 0.68
Mean intelligence score (SD): GIT
Intelligence (IQ) 109.3 (15.1) 106.3 (15.4) 0.38
Verbal reasoning 52.1 (10.6) 50.0 (10.1) 0.36
Visuospatial reasoning 49.8 (12.0) 51.1 (12.9) 0.64
Numerical speed 51.5 (10.2) 45.3 (10.2) 0.01
Mean memory score (SD)
Rey’s AVLT immediate 47.8 (8.9) 43.5 (8.9) 0.03
Rey’s AVLT delayed 48.5 (9.1) 44.7 (8.2) 0.05
Rey’s AVLT recognition 47.3 (11.4) 44.2 (13.9) 0.26
WMS-R immediate 52.1 (6.2) 49.8 (8.1) 0.15
WMS-R delayed 51.8 (6.8) 48.1 (11.4) 0.08
RBMT immediate 50.5 (10.9) 50.8 (8.6) 0.91
RBMT delayed 48.7 (11.3) 51.4 (10.1) 0.26
WAIS-R Digit Symbol Test 47.9 (8.7) 50.2 (10.6) 0.29
Mean language score (SD): Boston Naming Test 50.1 (14.9) 48.2 (16.4) 0.59
Mean attention score (SD)
Trail Making Test part B 48.2 (10.3) 42.0 (14.9) 0.03
SCWT part C (interference condition) 48.7 (12.4) 47.0 (16.2) 0.57
WAIS-R Digit Span Test 47.9 (8.7) 50.2 (10.6) 0.29
Mean executive functioning score (SD)
Category fluency 50.8 (12.0) 53.5 (10.5) 0.28
Letter fluency 49.1 (7.8) 47.7 (10.8) 0.50
Number of WCST categories 48.0 (6.9) 52.1 (11.7) 0.06
Number of WCST total errors 49.9 (8.7) 51.2 (12.8) 0.61
Number of WCST perseverative errors 47.7 (8.4) 47.1 (13.0) 0.82
Mean psychomotor speed score (SD)
Trail Making part A 49.8 (8.9) 43.8 (13.3) 0.01
SCWT Test part A (word reading) 47.8 (9.7) 48.1 (12.1) 0.93
SCWT part B (color naming) 46.3 (11.3) 47.0 (11.8) 0.79
Visual reaction task, dominant hand 49.2 (7.4) 45.9 (12.8) 0.15
Visual reaction task, nondominant hand 49.5 (7.0) 47.2 (13.7) 0.33
Binary choice reaction task 50.7 (9.3) 48.1 (15.1) 0.34
Scores are expressed as T-scores correczay2354.tifted for age and education.
aTwo-tailed p values (t test).
bTwo-tailed p value of Mann–Whitney U test.
SD  standard deviation; IQ  intelligence quotient; GIT  Groningen Intelligence Tests; AVLT  Auditory Verbal Learning Test; WMS-
R  Wechsler Memory Scale-Revised; RBMT  Rivermead Behavioural Memory Test; WAIS-R  Wechsler Adult Intelligence Scale-Revised;
SCWT  Stroop Color Word Test; WCST  Wisconsin Card Sorting Test.
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Discussion
Our results show that treatment with adjunctive dexa-
methasone is not associated with an increased risk for
long-term cognitive impairment in adults with bacterial
meningitis. Because adjunctive dexamethasone has be-
come routine therapy in adults with suspected bacterial
meningitis, this is important information for patients
and their treating physicians. Our prospective study
comprises the largest number of patients with long-
term neurological and neuropsychological evaluation
after bacterial meningitis to date and has enough power
to detect relevant differences between the dexametha-
sone and placebo groups.
Treatment with adjunctive dexamethasone is associ-
ated with a reduced risk for an unfavorable outcome,
including mortality, in adults with bacterial meningi-
tis.6,7 Although treatment with adjunctive dexametha-
sone was not associated with apparent side effects in
the European study, concerns existed about the effects
on long-term cognitive outcome.13 In vitro studies
have shown that corticosteroids are toxic to cultured
hippocampal and cortical neurons.28 Animal studies
demonstrated that striatal and hippocampal neurons
are particularly vulnerable to dexamethasone.29,30 In
addition, dexamethasone therapy increased hippocam-
pal apoptosis and learning deficiencies in experimental
bacterial meningitis.10,31 The dosage of dexamethasone
used in these experimental studies and the European
study were similar (0.7mg/kg/day).10 Corticosteroid-
induced damage of hippocampal neurons may account
for some of the cognitive deficits that have been noted
in healthy volunteers.29,30 In a study on long-term ef-
fects of early postnatal dexamethasone therapy for lung
disease of prematurity, steroids were associated with
impairments in neuromotor and cognitive function at
school age.32 Our analyses showed no significant group
differences between patients treated with adjunctive
dexamethasone and placebo within any of the cognitive
domains. Therefore, treatment with adjunctive dexa-
methasone does not worsen long-term cognitive out-
come in adults after bacterial meningitis.
We found that 13% of the patients who survived
bacterial meningitis had cognitive impairment. These
results are identical to those of our previous study in
which neuropsychological testing was performed in 51
adults with good recovery after bacterial meningitis.5 A
recent German study evaluating cognitive outcome 1
to 12 years after bacterial meningitis found a much
higher rate of cognitive impairment (37%).33 These
differences are explained by different criteria for cogni-
tive dysfunction. The German study used less strict cri-
teria, resulting in impaired cognitive functioning of the
control subjects ranging from 7 to 27% per domain. If
our criteria for cognitive dysfunction (score worse than
the fifth centile of control group) were applied to the
German study, 10% of the patients in their study
would have been rated as cognitively impaired.33
Patients after pneumococcal meningitis are at high
risk for cognitive impairment. Cognitive impairment
was found in 21% of the patients who survived pneu-
mococcal meningitis. Patients after meningococcal
meningitis had scores similar to those of the control
subjects. These findings agree with our previous study
that found cognitive impairment in 27% of the adults
who made a good recovery after pneumococcal menin-
gitis.5 The recent German study found no differences
in cognitive outcome between survivors of pneumococ-
cal and meningococcal meningitis33; however, these
discordant findings may well be explained by the lim-
ited number of patients in the latter study.11
The main cognitive impairment in patients after
pneumococcal meningitis consisted of memory deficits.
Previous studies on cognitive outcome in adults who
survived bacterial meningitis described cognitive slow-
ness, impairment of psychomotor and visuoconstruc-
tive performance, and higher scores on depression
scales.5,27,33–35 Our findings agree with previous obser-
vations.5,27,33 Hippocampal damage has been related to
learning and memory deficits in humans and in animal
models.10 This suggests that neuronal apoptosis in the
hippocampal dentate gyrus represents the major neuro-
pathological process responsible for cognitive impair-
ment in survivors of bacterial meningitis.
Cognitive speed was not related to time since men-
ingitis. This is in contrast with our previous study,
which suggested that loss of cognitive speed might be
partially reversible in time.27 This might well be ex-
plained by the longer time interval between meningitis
and neuropsychological evaluation in this study com-
pared with those previous studies (median, 8 years in
this study [range, 30 months to 12 years] vs 14 months
[range, 7–25 months]5 and 17 months [range, 6
months to 4 years],27 respectively). Our findings imply
that neuropsychological impairment improves in the
first years after bacterial meningitis and becomes rela-
tively stable with time.
The association of adjunctive dexamethasone therapy
with test results within the domain of memory differed
between patients after pneumococcal and meningococ-
cal meningitis. Whereas patients after pneumococcal
meningitis that received steroid therapy performed
slightly better on several memory-dependent tasks than
those in the placebo group, our analyses showed a re-
verse association in the subgroup of meningococcal pa-
tients. Although these findings may have been due to
chance, they are in line with the conflicting results of
steroids on neuronal injury in experimental meningitis
studies.10,12,36 Animal models of bacterial meningitis
showed that a more severe inflammatory response
within the subarachnoid space is associated with an in-
creased risk for adverse outcome and neurological se-
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quelae.37 Although antiinflammatory treatment with
corticosteroids can reduce the severity of CSF inflam-
mation, dexamethasone increased hippocampal apopto-
sis in infant rats with pneumococcal meningitis.10 In
contrast with these findings, adjunctive dexamethasone
reduced acute brain injury and attenuated meningitis-
induced memory deficits in mature rats after recovery
from meningitis with group B Streptococcus.36 Because
the inflammatory response and apoptotic pathways are
both related to meningitis-induced brain damage,38 the
lack of a negative effect of steroid therapy on cognitive
outcome in this study may reflect potential steroid-
induced brain injury being offset by the beneficial ef-
fects of inflammation or other not-yet-identified bene-
ficial effects. Therefore, the effect of adjunctive
dexamethasone on neuronal injury and cognitive out-
come in bacterial meningitis may, in part, depend on
the causative pathogen, the patient’s age, and the se-
verity of infection.
The most important limitation of our study was se-
lection bias. Because our study evaluated patients who
were previously included in a randomized, controlled
trial, all patients met specific inclusion criteria. Baseline
characteristics of patients in the European Dexametha-
sone Study were similar to those included in our
nation-wide cohort of adults with culture-proved bac-
terial meningitis.1 Therefore, patients included in the
European study are likely to be a representative sample
of adults with bacterial meningitis. Of the potentially
eligible patients in this study, 15% could not be con-
tacted for participation in this study. This relatively
high rate is probably due to the long time interval to
the start of this follow-up study (11 years) and the
anonymous inclusion of patients in the initial study.
Although demographic characteristics and the score on
the GOS 8 weeks after discharge in these lost-to-
follow-up patients were similar to the other patients,
this lack of follow-up data may have confounded our
results.
In conclusion, we found that treatment with adjunc-
tive dexamethasone is not associated with an increased
risk for long-term cognitive impairment. In addition,
our results show that adults who survive pneumococcal
meningitis are at significant risk for long-term cogni-
tive sequelae. Neuropsychological assessment can be
useful as an additional outcome measure in studies on
neurological infectious diseases.
Appendix
Neuropsychological Tests and Questionnaires
Boston Naming Test (short version): The short version of
this test consists of a visual picture naming task in
which 30 drawings are shown. These pictures are
presented in order of difficulty. Score is number of
correctly named pictures.
Dutch Adult Reading Test (DART): Fifty words with
irregular spelling have to be read aloud. The num-
ber of correctly read words is transformed into an
estimate of verbal intelligence. The DART is the
Dutch counterpart of the National Adult Reading
Test (NART). This test gives an estimate of pre-
morbid verbal intelligence, because it correlates
highly with other tests of verbal intelligence, al-
though it is relatively insensitive to cognitive dete-
rioration due to neurological disorders. Scores are
intelligence quotients (population mean, 100; stan-
dard deviation, 15).
Groningen Intelligence Test (GIT), subtest Verbal Reason-
ing: The subject has to choose one word from five
possibilities that correctly completes a 3  2 ma-
trix of logical semantic relations (eg, black-white,
high-low, hot-?).
GIT, subtest Visuospatial Reasoning: The subject has to
decide which of several smaller geometric shapes
are needed to fill a larger geometric figure (in a
way similar to the oriental game of Tangram, but
without actually manipulating the shapes).
GIT, subtest Numerical Speed: The subject completes as
many written additions as possible in 1 minute.
Rey’s Auditory Verbal Learning Test (AVLT): The sub-
ject has to memorize a series of 15 words in 5
learning trials. The test consists of an immediate
recall task, a delayed recall task, and a recognition
task.
Subtest Visual Reproduction of the Wechsler Memory
Scale-Revised (WMS-R): Four geometric figures of
increasing complexity are shown to the subject for
10 seconds each. Immediately after presentation of
each figure and after a 30-minute delay, the sub-
ject is asked to draw the figures from memory.
The quality of the drawings is scored by use of 41
criteria, resulting in a raw score range of 0 to 41.
Stroop Color Word Test (SCWT): This test measures
perceptual interference, response inhibition, and
selective attention by having the subject read the
names of 100 colors printed on a card (card 1),
name the color of ink of colored squares (card 2),
and name the color of ink of 100 nonmatching
color words (card 3). Score is time to completion
in seconds.
Subtest Story Recall of the Rivermead Behavioural Mem-
ory Test (RMBT): Two 21-item news messages are
read to the subject, who repeats as many items as
he or she can remember. After a 15-minute inter-
val, the subject is asked to recall the message again.
Trail Making Test: The task is to connect consecutive
numbers (part A) or numbers alternating with let-
ters (part B) on a sheet of paper. This is a test of
visual scanning, visuomotor and conceptual track-
ing, mental flexibility, and motor speed.
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Wisconsin Card Sorting Test (WCST): This test uses a
deck of cards on which different numbers of dif-
ferent forms in different colors are shown. The
task is to sort the cards according to one of three
possible sorting rules (color, number, or form).
These rules are not told but must be determined
by the subject. After each sort, feedback is given
on whether it was correct. Once a sorting rule has
been found (10 correct sorts on a row), the subject
has to change to a different rule. Of particular in-
terest are perseverative errors of the kind where the
subject keeps sorting according to a previously cor-
rect rule or to a rule that was wrong in the imme-
diately preceding sort. The WCST is a test of con-
cept formation and set shifting. Scores used in this
study are the raw numbers of errors and persevera-
tions.
GIT, Category Fluency: For 1 minute, the subject has to
say as many words that belong to a particular se-
mantic category. Two trials were done (animals
and occupations).
Letter Fluency (Controlled Oral Word Association Test
[COWAT]): For 1 minute, the subject has to say
as many words that begin with a given letter.
Three trials with different letters were done.
Simple reaction speed: Simple reaction speed was tested
for the dominant and nondominant hands sepa-
rately with use of visual stimuli. Scores are median
reaction times in milliseconds.
Two-choice reaction speed: Two-choice reaction speed
was tested with use of both hands and visual stim-
uli. Scores are median reaction times in millisec-
onds.
Grooved Pegboard: Fine motor skills and visual motor
coordination were tested for the dominant and
nondominant hands separately with use of a board
with 25 holes with randomly positioned slots in
which cones have to be inserted. Score is time to
completion in seconds.
Subtest Digit Span of Wechsler Adult Intelligence Scale-
Revised (WAIS-R): Subjects have to listen to in-
creasingly longer lists of digits and to produce im-
mediate recall in the actual and in reverse order
from initial presentation. This test is a measure of
attention, as well as working memory.
RAND-36: The RAND-36 is a questionnaire of general
health and quality of life. It has been standardized
for the Netherlands on a sample of subjects (n 
1,063) that is roughly comparable with the present
groups with respect to age and education.
Profile of Mood States (POMS): During the test session,
an abbreviated version of the POMS was filled out
by the patient. This is a list of 32 adjectives clus-
tered in 5 subscales (depression, anger, fatigue,
vigor, and tension) by which subjects describe
their mood during the preceding week.
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